Entero Therapeutics Q1 2025: Assets Near Liabilities
Ticker: GRDX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Entero Therapeutics Q1 2025: Assets $4.76M, Liabilities $4.75M. Tight spot.
AI Summary
Entero Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $4.76 million and total liabilities of $4.75 million. Revenue for the period was not explicitly stated, but the filing indicates a net loss. The company was formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc.
Why It Matters
This filing provides a snapshot of Entero Therapeutics' financial health at the end of Q1 2025, showing a near balance between assets and liabilities, which is crucial for investors assessing solvency.
Risk Assessment
Risk Level: medium — The company's assets are nearly equal to its liabilities, indicating a potentially precarious financial position.
Key Numbers
- $4.76M — Total Assets (As of March 31, 2025)
- $4.75M — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Filer
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- $4.76 million (dollar_amount) — Total assets as of March 31, 2025
- $4.75 million (dollar_amount) — Total liabilities as of March 31, 2025
- March 31, 2025 (date) — Reporting period end date
FAQ
What was Entero Therapeutics' net income or loss for the quarter ending March 31, 2025?
The filing indicates a net loss for the period, though the specific dollar amount is not immediately clear from the provided snippet.
What is the company's primary business activity?
The company is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
When did Entero Therapeutics change its name from First Wave BioPharma, Inc.?
The date of the name change from First Wave BioPharma, Inc. was September 21, 2021.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the business address of Entero Therapeutics?
The business address is 777 Yamato Road, Suite 502, Boca Raton, FL 33431.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Entero Therapeutics, Inc. (GRDX).